-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Anterior temporal lobe degeneration (FTD) is the second leading cause of early-onset dementia after Alzheimer's disease (AD)
.
FTD is characterized by changes in behavior and/or language due to the relatively selective atrophy of the frontal and temporal lobes
diagnosis
There are three main clinical manifestations of FTD
.
The behavioral variant of FTD (bvFTD) is defined by early and prominent behavioral and performance difficulties syndromes, and its core symptoms were revised by Rascovsky et al.
For example, bvFTD can be caused by tau, TDP-43 or rarer lesions.
Conversely, a lesion, such as PSP, can manifest as several clinical syndromes
In the recent dementia cohort, FTD cases were found to account for 1.
However, in addition to research purposes, whether improving the diagnosis of FTD at the population level can withstand cost-benefit analysis is a topic that should be discussed publicly
.
The differential diagnosis of dementia is an expensive risk, which can be questioned without changing the treatment of the disease
In this way, Mélanie Leroy of CHU Lille, Lille Neuroscience & Cognition, France, conducted this study in a large regional memory clinic (MC) network to better understand the FTD syndrome defined by the latest diagnostic criteria The incidence, characteristics and natural history of the disease
.
The purpose is to study the characteristics of FTD patients referred to the network from January 2010 to December 2016, including age of onset, time of diagnosis, clinical manifestations, cognitive progress, and treatment
They included patients who were first referred to our network between January 2010 and December 2016, whose final clinical diagnosis was degenerative or vascular dementia
.
The comparison between FTD and AD and between different FTD syndromes is divided into language variants (lvFTD), behavior variants (bvFTD) and FTD with mainly motor symptoms (mFTD)
Blood vessel
Of the patients referred to our network in 6 years, 690 were eventually diagnosed with FTD and 18,831 were diagnosed with AD
.
Patients with FTD syndrome account for 2.
The age-standardized incidence rate is 2.
90 per 100,000 person-years, and the incidence peaks between 75 and 79 years of age
.
Compared with AD, patients with FTD syndrome have longer delays in referral and diagnosis
.
Patients with FTD syndrome had a higher MMSE score at the time of first referral than AD, and their disease progression was similar
.
The survival time of mFTD patients is the shortest, but there is no significant difference in the survival time of bvFTD, lvFTD and AD
.
FTD patients, especially those with behavioral variations, receive more antidepressants, anti-anxiety drugs, and antipsychotics than AD patients
.
The important significance of this study lies in the discovery: FTD syndrome is different from AD in terms of baseline characteristics, progression rate and treatment
.
Despite the widespread use of new diagnostic criteria in an organized network of memory clinics, the diagnosis of FTD syndrome takes a long time and accounts for a low proportion of dementia cases, which indicates continued underdiagnosis
.
Original source: the Méotis network, Leroy M, Bertoux M, et al.
Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic network .
Alz Res Therapy.
2021;13(1):19.
doi:10.
1186/s13195- 020-00753-9
Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic networkLeave a message here
